Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-25

Foghorn Therapeutics (FHTX)

CEO Adrian Gottschalk was paid $2,361,027 in fiscal year 2025, ↑ up 51.4% from fiscal year 2024 (SEC filing 0001193125-26-193928 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,361,027 ↑
Adrian Gottschalk total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
98.98%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

FHTX's next annual pay disclosure, estimated April 25, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Adrian Gottschalk$638,000$0$0$1,334,037$385,990$0$3,000$2,361,027
President and Chief Executive Officer
Steven Bellon505,00000469,255222,20003,0001,199,455
Chief Scientific Officer
Alfonso Quintas-Cardama494,00000419,605217,36003,0001,133,965
Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Adrian Gottschalk$2,361,027$1,559,562$2,503,942↑ +801,465
Steven Bellon1,199,455902,2121,187,494↑ +297,243
Alfonso Quintas-Cardama1,133,965769,4891,844,535↑ +364,476

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Foghorn Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper FHTX reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against FHTX
8 companies name FHTX as a compensation peer

The list of companies that name FHTX as a peer is temporarily unavailable — recheck shortly.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
B. Lynne ParshallIndependent Director$151,754
Balkrishan (Simba) Gill, Ph.DIndependent Director$151,037
Douglas G. Cole, M.DChair of the Board$177,321
Ian F. SmithIndependent Director$131,970
Michael Mendelsohn, M.DIndependent Director$147,321
Neil J. Gallagher, M.D., Ph.DIndependent Director$193,002
Scott Biller, Ph.DIndependent Director$136,754
Stuart DutyIndependent Director$194,669
Thomas J. Lynch Jr., M.DIndependent Director$140,087
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Douglas G. ColeDirector2026-06-24A28,000$4$114,240Derivative, Class A CommonForm 4 ↗
B. Lynne ParshallDirector2026-06-24A28,0004114,240Derivative, Class A CommonForm 4 ↗
Simba GillDirector2026-06-24A28,0004114,240Derivative, Class A CommonForm 4 ↗
Ian F. SmithDirector2026-06-24A28,0004114,240Derivative, Class A CommonForm 4 ↗
Michael MendelsohnDirector2026-06-24A28,0004114,240Derivative, Class A CommonForm 4 ↗
Neil GallagherDirector2026-06-24A28,0004114,240Derivative, Class A CommonForm 4 ↗
Scott BillerDirector2026-06-24A28,0004114,240Derivative, Class A CommonForm 4 ↗
Stuart DutyDirector2026-06-24A28,0004114,240Derivative, Class A CommonForm 4 ↗
Thomas J. Lynch Jr.Director2026-06-24A28,0004114,240Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Steven BellonOption—————$469,255
Adrian GottschalkOption—————1,334,037
Alfonso Quintas-CardamaOption—————419,605
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Steven Bellon$0$0$469,2550.0%
Adrian Gottschalk001,334,0370.0%
Alfonso Quintas-Cardama00419,6050.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Steven BellonOption61,8753.06—
Steven BellonOption9,37514.87—
Steven BellonOption140,0004.37—
Adrian GottschalkOption87,5008.38—
Alfonso Quintas-CardamaOption119,0007.57—
Adrian GottschalkOption400,0004.37—
Alfonso Quintas-CardamaOption125,0004.37—
Alfonso Quintas-CardamaOption33,7503.06—
Adrian GottschalkOption27,50014.87—
Steven BellonOption31,2508.38—
Adrian GottschalkOption168,7503.06—
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation philosophy is designed to aid in attracting and retaining a high caliber workforce capable of delivering results at the leading edge of science, medicine, and business.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantPay Governance, LLC
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-2445,637,005468,9475,50098.98%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-2498.98%a

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the results of the vote on Proposal 3.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Stuart DutyIndependent · Audit · Newly elected$31,667$0$163,002—$0$194,669
Neil J. Gallagher, M.D., Ph.DIndependent · Science · Newly elected30,0000163,002—0193,002
Douglas G. Cole, M.DIndependent · Board Chair · Compensation · Nominating/Governance (Chair)85,351091,970—0177,321
B. Lynne ParshallIndependent · Audit (Chair) · Nominating/Governance59,784091,970—0151,754
Balkrishan (Simba) Gill, Ph.DIndependent · Audit · Compensation (Chair)59,067091,970—0151,037
Michael Mendelsohn, M.DIndependent · Compensation · Science (Chair)55,351091,970—0147,321
Thomas J. Lynch Jr., M.DIndependent · Nominating/Governance · Science48,117091,970—0140,087
Scott Biller, Ph.DIndependent · Science44,784091,970—0136,754
Ian F. SmithIndependent · Compensation40,000091,970—0131,970
Adrian GottschalkEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)6,000 / 10,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$454,121
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$454,121

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Foghorn Therapeutics2025Adrian Gottschalk$638,000$0$1,334,037$385,990$2,361,027

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Foghorn Therapeutics in fiscal 2025?
As disclosed, Adrian Gottschalk (President and Chief Executive Officer) was the highest-paid executive at Foghorn Therapeutics in fiscal 2025, with total compensation of $2,361,027.
How did shareholders vote on Foghorn Therapeutics's executive compensation?
As disclosed, 98.98% of shareholders supported Foghorn Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Foghorn Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Foghorn Therapeutics reported total board compensation of $454,121 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Adrian GottschalkDEF 14A2026-04-300001193125-26-193928Section “Summary Compensation Table”. As printed: 2,361,027. Filing ↗machine: r2 · c34 · span 245360–245369
2Section 01, Steven BellonDEF 14A2026-04-300001193125-26-193928Section “Summary Compensation Table”. As printed: 1,199,455. Filing ↗machine: r5 · c34 · span 250429–250438
3Section 01, Alfonso Quintas-CardamaDEF 14A2026-04-300001193125-26-193928Section “Summary Compensation Table”. As printed: 1,133,965. Filing ↗machine: t93 · r8 · c34 · span 255495–255504
4Section 03, Steven Bellon OptionDEF 14A2026-04-300001193125-26-193928Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t93 · r5 · c19 · span 249546–249553
5Section 03, Adrian Gottschalk OptionDEF 14A2026-04-300001193125-26-193928Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t93 · r2 · c19 · span 244475–244484
6Section 03, Alfonso Quintas-Cardama OptionDEF 14A2026-04-300001193125-26-193928Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
7Section 07, pay ratio10-K2026-03-110001628280-26-016814Section “CEO Pay Ratio”. As printed: —. Filing ↗
8Section 08, Stuart DutyDEF 14A2026-04-300001193125-26-193928Section “Director Compensation”. As printed: 194,669. Filing ↗machine: t119 · r4 · c14 · span 349040–349047
9Section 08, Neil J. Gallagher, M.D., Ph.DDEF 14A2026-04-300001193125-26-193928Section “Director Compensation”. As printed: 193,002. Filing ↗machine: t119 · r5 · c14 · span 350205–350212
10Section 08, Douglas G. Cole, M.DDEF 14A2026-04-300001193125-26-193928Section “Director Compensation”. As printed: 177,321. Filing ↗machine: t119 · r2 · c14 · span 346710–346717
11Section 08, B. Lynne ParshallDEF 14A2026-04-300001193125-26-193928Section “Director Compensation”. As printed: 151,754. Filing ↗machine: t119 · r9 · c14 · span 354879–354886
12Section 08, Balkrishan (Simba) Gill, Ph.DDEF 14A2026-04-300001193125-26-193928Section “Director Compensation”. As printed: 151,037. Filing ↗machine: t119 · r6 · c14 · span 351384–351391
13Section 08, Michael Mendelsohn, M.DDEF 14A2026-04-300001193125-26-193928Section “Director Compensation”. As printed: 147,321. Filing ↗machine: t119 · r8 · c14 · span 353725–353732
14Section 08, Thomas J. Lynch Jr., M.DDEF 14A2026-04-300001193125-26-193928Section “Director Compensation”. As printed: 140,087. Filing ↗machine: t119 · r7 · c14 · span 352539–352546
15Section 08, Scott Biller, Ph.DDEF 14A2026-04-300001193125-26-193928Section “Director Compensation”. As printed: 136,754. Filing ↗machine: t119 · r3 · c14 · span 347866–347873
16Section 08, Ian F. SmithDEF 14A2026-04-300001193125-26-193928Section “Director Compensation”. As printed: 131,970. Filing ↗machine: t119 · r10 · c14 · span 355936–355943
17Section 08, Adrian GottschalkDEF 14A2026-04-300001193125-26-193928Section “Director Compensation”. As printed: 0. Filing ↗
18Section 02, Douglas G. Cole 2026-06-24Form 42026-06-250001486373-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, B. Lynne Parshall 2026-06-24Form 42026-06-250001073385-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Simba Gill 2026-06-24Form 42026-06-250001180763-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Ian F. Smith 2026-06-24Form 42026-06-250001197032-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Michael Mendelsohn 2026-06-24Form 42026-06-250001591109-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Neil Gallagher 2026-06-24Form 42026-06-250001972849-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Scott Biller 2026-06-24Form 42026-06-250001581956-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Stuart Duty 2026-06-24Form 42026-06-250001970274-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Thomas J. Lynch Jr. 2026-06-24Form 42026-06-250001474056-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
27Section 06, 2026 voteForm 8-K2026-06-240001628280-26-045154Item 5.07 · say-on-pay result. As reported: 98.98% (votes for as printed: 45,637,005). Filing ↗
28Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
29Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
30Section 09b board cost (computed)Computed——Cash 454,121 + equity 0 + all other 0 = 454,121, summed across the director compensation table rows.machine: formula: Σ = 454,121
31Foghorn Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-300001193125-26-193928CEO total compensation as printed in Foghorn Therapeutics's own proxy. As printed: 2,361,027. Filing ↗machine: r2 · c34 · span 245360–245369

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.